GAMMA Investing LLC Purchases 666 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN)

GAMMA Investing LLC lifted its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 22.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 3,641 shares of the medical equipment provider’s stock after purchasing an additional 666 shares during the quarter. GAMMA Investing LLC’s holdings in Smith & Nephew SNATS were worth $103,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in SNN. National Bank of Canada FI grew its holdings in Smith & Nephew SNATS by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 446 shares during the last quarter. Hara Capital LLC grew its holdings in Smith & Nephew SNATS by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 1,957 shares during the last quarter. Versant Capital Management Inc grew its holdings in Smith & Nephew SNATS by 1,970.2% during the 1st quarter. Versant Capital Management Inc now owns 5,217 shares of the medical equipment provider’s stock worth $148,000 after acquiring an additional 4,965 shares during the last quarter. Quadrant Capital Group LLC grew its holdings in Smith & Nephew SNATS by 37.4% during the 4th quarter. Quadrant Capital Group LLC now owns 7,431 shares of the medical equipment provider’s stock worth $183,000 after acquiring an additional 2,024 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in Smith & Nephew SNATS by 4.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider’s stock worth $224,000 after acquiring an additional 399 shares during the last quarter. Institutional investors own 25.64% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on SNN. HSBC downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Friday, April 25th. Hsbc Global Res downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. Canaccord Genuity Group upped their target price on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a “hold” rating in a research report on Thursday, May 1st. Finally, UBS Group downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 12th. Six research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.00.

Smith & Nephew SNATS Price Performance

Shares of SNN opened at $30.26 on Monday. The stock has a market capitalization of $13.25 billion, a P/E ratio of 14.01, a P/E/G ratio of 0.93 and a beta of 0.69. Smith & Nephew SNATS, Inc. has a twelve month low of $23.69 and a twelve month high of $31.72. The company has a 50 day moving average of $29.07 and a 200-day moving average of $27.30. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.